The shift under way in payment in US health care - from volume to value - has sparked interest in new contracting arrangements to pay for prescription drugs. The objective of these new arrangements is to reward successful outcomes of medication use in patients, rather than pay based on the volume of drugs sold. These value-based contracts represent one approach to managing drug costs and obtaining better value for money spent. However, achieving the full potential of these contracts will necessitate regulatory and other changes.
Catherine Davis Ahmed, Director of Outreach, Familial Hypercholesterolemia Foundation
Michelle Drozd, Deputy Vice PresidentPharmaceutical Research and Manufacturers of America
David Hartenbaum, Executive Director, Account Management, Merck
Dorothy Hoffman, Director, Healthcare Transformation and Policy Partnerships, Eli Lilly
Surya Singh, MD, Executive Vice President and Chief Medical Officer of CVS/Specialty